Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.62 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14451968 | 0.82 | SLC6A2 (0.49) | TAAR1AOC3KDM4ESLC6A2SLC6A3 | |
| SCHEMBL1968535 | 0.81 | HTR2A (0.55) | TAAR1HTR2AKDM4EGRIN2BSLC6A2 | |
| SCHEMBL27817763 | 0.79 | TAAR1 (0.62) | TAAR1AOC3HTR2AKDM4EGRIN2B | |
| SCHEMBL2909631 | 0.77 | TAAR1 (1.00) | TAAR1AOC3HTR2AKDM4EALDH1A1 | |
| SCHEMBL1965745 | 0.77 | AOC3 (0.61) | TAAR1AOC3HTR2ACHRM2BCHE | |
| SCHEMBL16367151 | 0.76 | SLC6A2 (0.44) | TAAR1AOC3KDM4ESLC6A2SLC6A3 | |
| SCHEMBL2405275 | 0.75 | SLC6A4 (0.57) | HTR2A | |
| SCHEMBL2405790 | 0.75 | HTR2A (0.71) | HTR2AALDH1A1 | |
| SCHEMBL1967143 | 0.74 | GRIN2B (0.63) | TAAR1AOC3HTR2AKDM4EGRIN2B | |
| SCHEMBL24776468 | 0.73 | HTR2A (0.55) | TAAR1AOC3HTR2AKDM4ESLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | TAAR1 48/4885AOC3 550/4885HTR2A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.